Zejing Pharmaceuticals: the clinical trial application for the combination of injection ZG005 and injection ZGGS18 has been approved by the FDA.

Zejing Pharmaceuticals announced that recently, the company's application for a clinical trial of the combination of injectable ZG005 and injectable ZGGS18 for the treatment of advanced solid tumors has been approved by the U.S. Food and Drug Administration. This clinical trial approval will not have a significant impact on the company's recent performance.